Hyundai Bioscience현대바이오

Hyundai Bioscience remains loss-making with shrinking revenue, while its share price is well below its 52-week high.

The company sold about ₩3.3B of revenue over the trailing twelve months to H1 2026 against an operating loss of ₩19.3B, after revenue fell sharply in 2025 from ₩15.1B in 2024. It is developing a new drug for SFTS alongside its cosmetics business, and its filings show ongoing heavy losses and negative free cash flow.

What stands out

• Trailing revenue is ₩3.3B with an operating loss of ₩19.3B and a net loss of ₩28.6B, giving an operating margin of about -580%.
• Cash of ₩17.1B is below borrowings of ₩21.3B, and trailing free cash flow is about -₩16.5B.
• Annual revenue fell 76.6% in 2025 after a 58.7% rise in 2024, and 2024 was the only recent year with a small operating profit.
• The share price closed at ₩6,160, down 9.8% over one month and 6% over three months, but up 16.2% over one year; it is far below the 52-week high of ₩21,500.
• The latest news item is a plan to develop an SFTS treatment and move quickly into Phase 2 trials; the filings list mainly shareholding reports and an amended half-year report.

What to watch

• Upcoming full-year and half-year results and whether the amended June 2026 half-year report changes the reported figures.
• Progress on the SFTS drug programme toward Phase 2 trials, including any funding needs given the cash and borrowings position.
• Ongoing 5%+ holding and insider shareholding filings, and the foreign ownership decline from 7.7% to 6% over the past 60 days.